

Antinuclear Antibody Immunofluorescence Patterns and Their Clinical Correlations in Patients with Systemic Lupus Erythematosus: A Study from a Tertiary Center in Nepal

Prabin Khatri,^{*,1} Ravi Shukla,² Raj Adhikari,¹ Aabishkar Subedi,¹ Puja Shrestha,¹ Mamata Bhattarai¹

Supplementary Table S1. Complete Clinical Features by ANA Pattern Group*

Clinical Domain	NH (n=76)	NFS (n=43)	NCS (n=28)	CFDS (n=9)	Others (n=11)	χ^2	p [#]	Cramer's V
Constitutional								
Fever	32 (42.11%)	15 (34.88%)	10 (35.71%)	5 (55.56%)	4 (36.36%)	5.28	0.25	—
Fatigue	25 (32.89%)	16 (37.21%)	10 (35.71%)	4 (44.44%)	1 (9.09%)	2.91	0.57	—
Musculoskeletal								
Arthralgia	32 (42.11%)	12 (27.91%)	10 (35.71%)	2 (22.22%)	3 (27.27%)	5.82	0.21	—
Arthritis	23 (30.26%)	7 (16.28%)	4 (14.29%)	2 (22.22%)	1 (9.09%)	5.32	0.02	0.18
Mucocutaneous								
Oral ulcers	17 (22.37%)	10 (23.26%)	7 (25.00%)	2 (22.22%)	1 (9.09%)	1.25	0.86	—
Non-scarring alopecia	14 (18.42%)	4 (9.30%)	3 (10.71%)	0 (0.00%)	0 (0.00%)	4.34	0.03	0.17
Malar rash	15 (19.74%)	19 (44.19%)	6 (21.43%)	2 (22.22%)	5 (45.45%)	7.37	0.01	0.21
Hematological								
AIHA	10 (13.16%)	5 (11.63%)	2 (7.14%)	0 (0.00%)	2 (18.18%)	2.41	0.66	—
Leukopenia	8 (10.53%)	2 (4.65%)	2 (7.14%)	0 (0.00%)	0 (0.00%)	3.27	0.51	—
Thrombocytopenia	12 (15.79%)	0 (0.00%)	2 (7.14%)	0 (0.00%)	0 (0.00%)	9.96	0.02	0.24
Neuropsychiatric								
Psychosis	5 (6.58%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	—	—	—
Seizures	0 (0.00%)	1 (2.33%)	1 (3.57%)	0 (0.00%)	0 (0.00%)	—	—	—
Serositis								
Pericardial [§]	1 (1.32%)	1 (2.33%)	0 (0.00%)	1 (11.11%)	1 (9.09%)	6.10	0.19	—
Pleural ^{&}	8 (10.53%)	2 (4.65%)	4 (14.29%)	0 (0.00%)	3 (27.27%)	6.49	0.16	—
Cardiac								
Myocarditis	8 (10.53%)	2 (4.65%)	5 (17.86%)	2 (22.22%)	1 (9.09%)	4.44	0.35	—
Renal								
Proteinuria	37 (48.68%)	14 (32.56%)	9 (32.14%)	4 (44.44%)	1 (9.09%)	2.37	0.67	—
Lupus nephritis	17 (22.37%)	6 (13.95%)	5 (17.86%)	1 (11.11%)	0 (0.00%)	6.33	0.01	0.20

*Percentages are column percentages. [§]pericarditis, pericardial effusion. [&]pleural effusion, pleuritis, pleurisy. "Others" includes AC-3, AC-6, AC-10, AC-11, AC-20, AC-21, and AC-26 (n = 11). [#]For clinical manifestations with expected cell frequencies <5 in some comparisons, Chi-square test results may be less reliable. These associations should be interpreted with caution and validated in larger cohorts.

Supplementary Table S2. Complete Immunological Markers by ANA Pattern Group*

Immunological Marker	NH (n=76)	NFS (n=43)	NCS (n=28)	CFDS (n=9)	Others (n=11)	χ^2	p [#]	Cramer's V
Direct Coombs test	16 (21.05%)	4 (9.30%)	1 (3.57%)	0 (0.00%)	0 (0.00%)	10.35	0.04	0.25
Lupus anticoagulant	30 (39.47%)	8 (18.60%)	2 (7.14%)	2 (22.22%)	2 (18.18%)	13.79	0.01	0.29
Anti-dsDNA	52 (68.42%)	9 (20.93%)	7 (25.00%)	2 (22.22%)	0 (0.00%)	42.45	<0.01	0.50
Anti-Smith (Sm)	14 (18.42%)	11 (25.58%)	11 (39.29%)	2 (22.22%)	1 (9.09%)	6.36	0.17	—
Anti-centromere	1 (1.32%)	2 (4.65%)	0 (0.00%)	0 (0.00%)	3 (27.27%)	15.42	0.05	—
Anti-histone	27 (35.53%)	7 (16.28%)	2 (7.14%)	2 (22.22%)	1 (9.09%)	11.85	0.01	0.32
Anti-nucleosome	49 (64.47%)	10 (23.26%)	6 (21.43%)	2 (22.22%)	0 (0.00%)	30.15	<0.01	0.43
Anti-Ro	21 (27.63%)	20 (46.51%)	14 (50.00%)	5 (55.56%)	3 (27.27%)	7.78	0.10	—
Anti-La/SSB	12 (15.79%)	8 (18.60%)	4 (14.29%)	0 (0.00%)	0 (0.00%)	4.13	0.39	—
Anti-Sm/RNP	20 (26.32%)	13 (30.23%)	18 (64.29%)	0 (0.00%)	1 (9.09%)	28.65	<0.01	—
Anti-RNP 68	4 (5.26%)	9 (20.93%)	15 (53.57%)	2 (22.22%)	0 (0.00%)	34.20	<0.01	—
Anticardiolipin IgG	21 (27.63%)	3 (6.98%)	4 (14.29%)	2 (22.22%)	0 (0.00%)	11.15	0.03	0.26
Anticardiolipin IgM	16 (21.05%)	7 (16.28%)	3 (10.71%)	2 (22.22%)	3 (27.27%)	2.28	0.69	—
Anti-β2GP1 IgG	3 (3.95%)	2 (4.65%)	1 (3.57%)	0 (0.00%)	1 (9.09%)	3.34	0.50	—
Anti-β2GP1 IgM	13 (17.11%)	3 (6.98%)	1 (3.57%)	0 (0.00%)	1 (9.09%)	6.48	0.16	—

*Percentages are column percentages. #For immunological markers with expected cell frequencies <5 in some comparisons, Chi-square test results may be less reliable. These associations should be interpreted with caution and validated in larger cohorts.